Company / Capital Expenditures
Arcturus Therapeutics Holdings Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$230.0K
FY2025
5-year range
$230.0K / $3.4M
FY2021-FY2025
Trend
-64.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has declined for 3 consecutive years, from $3M in FY2022 to $230,000 in FY2025.
Based on SEC 10-K filings.
$230,000 in FY2025 with a 5-year CAGR of -31.1%.
Declined from $3M to $230,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -59.3%
- 5-Year CAGR
- -31.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcturus Therapeutics Holdings Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of -31.1%, indicating a declining trend.
- In FY2025, capital expenditures decreased 64.5% year-over-year.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $230.0K | -64.5% |
| FY2024 | $648.0K | -77.7% |
| FY2023 | $2.9M | -14.8% |
| FY2022 | $3.4M | +0.0% |
| FY2021 | $3.4M | +130.4% |
| FY2020 | $1.5M | +0.0% |
| FY2019 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026